Angiotech's corporate partner, Boston Scientific, reports two-year SYNTAX data showing comparable safety outcomes for complex patients treated with Taxus(R) Express(R) stents and bypass surgery



    VANCOUVER and BARCELONA, Sept. 2 /CNW/ - Angiotech Pharmaceuticals, Inc.
(NASDAQ:   ANPI, TSX: ANP) today announced that its corporate partner, Boston
Scientific (NYSE:   BSX), has reported two-year data from its SYNTAX clinical
trial comparing percutaneous coronary intervention (PCI) using the Taxus(R)
Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass
graft (CABG) surgery. The overall results demonstrated no statistically
significant difference between PCI and CABG in the composite safety endpoint
(all-cause death, stroke and myocardial infarction (MI)). Boston Scientific
made the announcement at the annual European Society of Cardiology (ESC)
Congress in Barcelona.
    "These results reinforce the one-year SYNTAX data and show impressive
outcomes for PCI in patients with complex coronary anatomy, the majority of
whom are normally treated with CABG surgery," said Keith D. Dawkins, M.D.,
Associate Chief Medical Officer of Boston Scientific. "Today's findings build
on our prior data and provide additional support for PCI as a viable treatment
option for many of these challenging patients."
    The patients in the SYNTAX trial - all of whom have left main and/or
three-vessel coronary disease - are a unique study group in the PCI field. In
the SYNTAX trial, mean stent use was 4.6 stents/patient, with one patient
having 14 stents implanted. By contrast, the average number of stents
implanted in a PCI patient in everyday practice is 1.5. In addition, the study
included 33 percent of patients with (greater than)100 mm stented length, 71
percent with bi/trifurcations, 27 percent with chronic total occlusions and 39
percent with left main disease.
    The results showed comparable safety profiles for the two treatment
groups at two years, with a combined rate of all-cause death, stroke and MI of
10.8 percent for PCI and 9.6 percent for CABG (p=0.44). The rate of stroke was
1.4 percent for PCI as compared to 2.8 percent for CABG (p=0.03), while MI was
5.9 percent for PCI and 3.3 percent for CABG (p=0.01). The rate of all-cause
death was 6.2 percent for PCI and 4.9 percent for CABG (p=0.24).
    Overall MACCE (Major Adverse Cardiovascular or Cerebrovascular Event
rate, including all-cause death, stroke, MI and repeat revascularization) was
significantly higher for PCI (23.3 percent as compared to 16.4 percent for
CABG, p=0.0002), driven largely by the anticipated higher rate of
revascularization in the PCI group (17.4 percent as compared to 8.6 percent
for CABG, p(less than)0.0001), with the difference narrowing in the second
year of follow-up. Most patients requiring repeat revascularization in the PCI
group were successfully treated with another PCI.
    The trial results were also analyzed based on the SYNTAX Score, which
demonstrated no statistically significant difference in MACCE for patients in
the lower two terciles - those with low lesion complexity (19.4 percent for
PCI and 17.4 percent for CABG, p=0.63) and moderate lesion complexity (22.8
percent for PCI and 16.4 percent for CABG, p=0.06). For patients in the upper
tercile - those with the most complex disease - there was a significant
increase in MACCE for PCI patients as compared to CABG (28.2 percent as
compared to 15.4 percent, p=0.001).
    The SYNTAX Score is a novel angiographic tool used to measure the
complexity of coronary artery disease based on nine anatomic criteria,
including lesion frequency, complexity and location. Higher SYNTAX Scores
indicate patients with more complex disease and increased treatment
challenges. A SYNTAX Score website, www.syntaxscore.com, was launched in May
and allows cardiologists and cardiac surgeons to characterize a patient's
anatomical complexity, which can be used in combination with a physician's
clinical judgment to help determine the best revascularization option.
    The SYNTAX Score and SYNTAX Score website were developed under the
direction of the SYNTAX trial steering committee, chaired by Patrick Serruys,
M.D., Ph.D and F.W. Mohr, M.D., Ph.D., and were made possible by support from
Boston Scientific and Cardialysis BV.
    The safety and effectiveness of the TAXUS Express Stent System has not
been established in patients with left main or three-vessel disease.

    Forward Looking Statements

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 and constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2009 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada and the other
regions in which we operate; market demand; technological changes that could
impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental regulations and changes
in, or the failure to comply with, governmental regulations; availability of
financial reimbursement coverage from governmental and third-party payers for
products and related treatments; adverse results or unexpected delays in
pre-clinical and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; the requirement
for substantial funding to conduct research and development, to expand
manufacturing and commercialization activities; and any other factors that may
affect our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by the
forward-looking statements in this Press Release to differ materially from our
actual results. These operating risks include: our ability to attract and
retain qualified personnel; our ability to successfully complete pre-clinical
and clinical development of our products; changes in our business strategy or
development plans; our failure to obtain patent protection for discoveries;
loss of patent protection resulting from third-party challenges to our
patents; commercialization limitations imposed by patents owned or controlled
by third parties; our ability to obtain rights to technology from licensors;
liability for patent claims and other claims asserted against us; our ability
to obtain and enforce timely patent and other intellectual property protection
for our technology and products; the ability to enter into, and to maintain,
corporate alliances relating to the development and commercialization of our
technology and products; market acceptance of our technology and products; our
ability to successfully manufacture, market and sell our products; the
availability of capital to finance our activities; our ability to restructure
and to service our debt obligations; and any other factors referenced in our
other filings with the applicable Canadian securities regulatory authorities
or the Securities and Exchange Commission ("SEC"). For a more thorough
discussion of the risks associated with our business, see the "Risk Factors"
section in our annual report for the year ended December 31, 2008 filed with
the SEC on Form 10-K, and our quarterly report for the three months ended June
30, 2009 filed with the SEC on Form 10-Q. Given these uncertainties,
assumptions and risk factors, investors are cautioned not to place undue
reliance on such forward-looking statements. Except as required by law, we
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or developments.

    (C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.





For further information:

For further information: Irma Gomez-Dib, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (212) 850-5761,
irma.gomez-dib@fd.com; Sharrifah Al-Salem, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4414,
sharrifah.alsalem@fdashtonpartners.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890